Efficient high-throughput SARS-CoV-2 testing to detect asymptomatic carriers.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
09 2020
Historique:
received: 03 05 2020
accepted: 28 07 2020
entrez: 12 9 2020
pubmed: 13 9 2020
medline: 29 9 2020
Statut: epublish

Résumé

Recent reports suggest that 10 to 30% of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infected patients are asymptomatic and that viral shedding may occur before symptom onset. Therefore, there is an urgent need to increase diagnostic testing capabilities to prevent disease spread. We developed P-BEST, a method for Pooling-Based Efficient SARS-CoV-2 Testing, which identifies all positive subjects within a set of samples using a single round of testing. Each sample is assigned into multiple pools using a combinatorial pooling strategy based on compressed sensing. We pooled sets of 384 samples into 48 pools, providing both an eightfold increase in testing efficiency and an eightfold reduction in test costs, while identifying up to five positive carriers. We then used P-BEST to screen 1115 health care workers using 144 tests. P- BEST provides an efficient and easy-to-implement solution for increasing testing capacity that can be easily integrated into diagnostic laboratories.

Identifiants

pubmed: 32917716
pii: sciadv.abc5961
doi: 10.1126/sciadv.abc5961
pmc: PMC7485993
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Références

Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
Nat Commun. 2020 Sep 23;11(1):4812
pubmed: 32968075
Genome Res. 2009 Jul;19(7):1243-53
pubmed: 19447965
Lancet Microbe. 2020 Jul;1(3):e101-e102
pubmed: 32835337
Plant J. 2016 May;86(4):349-59
pubmed: 26959378
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Nucleic Acids Res. 2010 Oct;38(19):e179
pubmed: 20699269
Clin Infect Dis. 2020 Nov 19;71(16):2073-2078
pubmed: 32358960
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
JAMA. 2020 May 19;323(19):1967-1969
pubmed: 32250394
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):347-352
pubmed: 32214086
Clin Microbiol Infect. 2020 Sep;26(9):1248-1253
pubmed: 32585353
Lancet Infect Dis. 2020 Nov;20(11):1231-1232
pubmed: 32530425
mSphere. 2018 Jul 11;3(4):
pubmed: 29997120
Am J Clin Pathol. 2020 May 5;153(6):715-718
pubmed: 32304208
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32521222
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Genome Res. 2009 Jul;19(7):1254-61
pubmed: 19447964
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930

Auteurs

Noam Shental (N)

Department of Computer Science, The Open University of Israel, Ra'anana, Israel. angel@bgu.ac.il shental@openu.ac.il thertz@bgu.ac.il.

Shlomia Levy (S)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Vered Wuvshet (V)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Shosh Skorniakov (S)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Bar Shalem (B)

Department of Computer Science, Bar-Ilan University, Ramat Gan, Israel.

Aner Ottolenghi (A)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Yariv Greenshpan (Y)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Rachel Steinberg (R)

Soroka University Medical Center, Beer-Sheva, Israel.

Avishay Edri (A)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Roni Gillis (R)

Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Michal Goldhirsh (M)

Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Khen Moscovici (K)

Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Sinai Sachren (S)

National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Lilach M Friedman (LM)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Lior Nesher (L)

Soroka University Medical Center, Beer-Sheva, Israel.

Yonat Shemer-Avni (Y)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Soroka University Medical Center, Beer-Sheva, Israel.

Angel Porgador (A)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. angel@bgu.ac.il shental@openu.ac.il thertz@bgu.ac.il.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Tomer Hertz (T)

Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH